Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 3144 |
Synonyms | |
Therapy Description |
3144 is a Pan-RAS inhibitor, which binds to KRAS, NRAS, and HRAS proteins and decreases RAS-mediated signaling, and may reduce growth of RAS-dependent tumors (PMID: 28235199). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
3144 | RAS Inhibitor (Pan) 11 | 3144 is a Pan-RAS inhibitor, which binds to KRAS, NRAS, and HRAS proteins and decreases RAS-mediated signaling, and may reduce growth of RAS-dependent tumors (PMID: 28235199). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G13V | adult T-cell leukemia/lymphoma | sensitive | 3144 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199). | 28235199 |
NRAS G13D | adult T-cell leukemia/lymphoma | sensitive | 3144 | Preclinical - Cell culture | Actionable | In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199). | 28235199 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|